"Radiation dose to the prostate was the most significant determinant of cancer control for these high-risk prostate cancer patients," said Jacob. "The data we presented here indicate that the prostate is the major site of treatment failure in high-risk patients and that high doses are of paramount importance for this group."
High dose was considered to be more than 70 Gy. Short-term androgen deprivation was not an independent predictor for cancer control. Other study authors include Alexandra L. Hanlon, Ph.D., Eric M. Horwitz, M.D., Benjamin Movsas, M.D., Robert Uzzo, M.D., and Alan Pollack, M.D., Ph.D., of Fox Chase Cancer Center.
Fox Chase Cancer Center, one of the nation's first comprehensive cancer centers designated by the National Cancer Institute in 1974, conducts basic, clinical, population and translational research; programs of prevention, detection and treatment of cancer; and community outreach. For more information about Fox Chase activities, visit the Center's web site at www.fccc.edu or call 1-888-FOX CHASE.